Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether left ventricular function improves more
rapidly with deferoxamine (DFO) and deferiprone (L1) combination therapy than with DFO
monotherapy in patients with thalassemia and decreased ejection fractions. Secondary aims
include evaluating changes in myocardial iron burden using T2* and estimating the relative
incidence and severity of chelator-induced toxicity.